Aim-To establish if coincidental HLA-A, HLA-B, and HLA-DR tissue matching is associated with a reduced likelihood of corneal graft rejection. Methods-Organ culture preserved random donor corneas were used for penetrating keratoplasty (PKP). Corneal tissue from all graft recipients and donors or blood samples from recipients after repeated transplantation were obtained in order to perform retrospective molecular HLA typing. A group of 21 recipients with a rejection episode (cases) after corneal transplantation was compared with a control group of non-rejectors (n = 43). 31 graft recipients were considered as high risk patients. The influence of HLA-A, HLA-B, and HLA-DR matching on rejection free graft survival time was analysed with Kaplan-Meyer statistics and Cox regression. Results-A prolonged rejection free survival time was observed in graft recipients with one or two HLA-A matches (log rank test, p = 0.034). This eVect was also observed in high risk graft recipients with one or two HLA-DR matches (log rank test, p = 0.030). Conclusions-Coincidental HLA-A and HLA-DR matches were observed and associated with a prolonged rejection free survival time in the total group and in the high risk group, respectively. These results support the beneficial eVect of prospective HLA-A and HLA-DR typing upon corneal graft survival. (Br J Ophthalmol 2001;85:1341-1346 Corneal grafting is often a successful procedure. 1 In contrast with transplantation of other solid organs, no systemic immunosuppressive agents are needed to prevent allograft rejection.
Corneal grafting is often a successful procedure. 1 In contrast with transplantation of other solid organs, no systemic immunosuppressive agents are needed to prevent allograft rejection. 2 In avascular corneas, graft survival results of 85-95% were reported after 1 year of follow up. 1 3 Nevertheless, immunological allograft rejection is reported to be the leading cause of corneal graft failure. 3 4 The incidence of immune mediated graft rejection and failure is increased in high risk patients having corneal vascularisation or a history of graft rejection. [5] [6] [7] [8] It might be expected that corneal graft survival in high risk cases would increase after prospective human leucocyte antigen (HLA) class I matching of donor and recipient, 5 9-12 in accordance with HLA matching for increased graft survival of other solid organs. 13 14 However, the role of HLA matching in reducing corneal graft failure could not be confirmed by all studies. 3 15-18 A beneficial role of HLA-A and HLA-B matching can be explained by the finding that mismatched HLA class I antigens are immunogenic. 19 20 HLA class I antigens are targets for rejection by CD8+ cytotoxic T lymphocytes. 21 Organ culture preservation of donor corneas was shown to contribute to a reduction in the amount of HLA class II bearing Langerhans cells, [22] [23] [24] resulting in reduced antigenicity of the corneal graft. 19 25 This may lead to a decreased incidence of rejection. HLA-DR (class II) matching in cornea transplantation showed beneficial eVects 26 27 and an adverse eVect in another study. 28 This controversy may be explained partly by inadequacy of serological HLA-DR typing techniques. 29 Although HLA matched corneal grafts were rarely used in patients at high risk of rejection at the University Medical Centre of Utrecht, Netherlands, a relatively high success rate of corneal transplants was observed over the last 5 years. 30 With the recent availability of DNA based typing techniques 29 31 32 it is possible to perform HLA-A, HLA-B, and HLA-DR typing of recipients and donors retrospectively and accurately. [33] [34] [35] [36] The aim of this retrospective study was to examine whether diVerences exist with regard to molecular HLA-A, HLA-B, and HLA-DR matching and to rule out coincidental HLA matching between corneal graft recipients, with versus without immune mediated graft rejection.
Patients and methods

PATIENTS
Between February 1995 and December 1997 248 consecutive patients underwent PKP with random corneal grafts at the University Medical Centre of Utrecht, Netherlands. Patient charts were revised for age, sex, use of systemic immune suppression, a history of glaucoma or herpes simplex keratitis (HSK), tear film insufficiency, number of previous grafts, indication for transplantation, degree of stromal vascularisation of the recipient cornea at the time of PKP, additional surgical procedures during PKP, any rejection episodes, and the final outcome of the corneal graft. In the category of patients with a history of glaucoma we included patients with ocular hypertension or primary open angle glaucoma (POAG) based on use of antiglaucoma medication, neuropathy with an excavation of the optical nerve, defects in the visual field, a diagnosis of POAG, or an intraocular pressure above 23 mm Hg. Furthermore, information about the donors and donor corneas was collected; age, sex, graft size, and storage time of organ culture preservation. High risk criteria for corneal allograft failure were defined according to the presence of two or more quadrants of deep stromal vascularisation and/or previous immunologically mediated allograft failure(s). 9 Out of the group of 248 patients a case (n = 21) and control group (n = 43) were selected. Cases were all transplant recipients undergoing a rejection episode, according to strict criteria described below (n = 23). Patients for whom it was not possible to diVerentiate between irreversible graft rejection and graft failure due to other causes were not included. Patients in whom no corneal tissue was available for DNA isolation (n = 2, one patient grafted for Fuchs' dystrophy and the other for HSK) were excluded. The control group was formed out of a group of patients with at least 1 year of follow up after PKP and no episodes of graft rejection. This group was matched for age and sex. Patients with graft failure because of other causes than rejection were not excluded as long as their cornea could be evaluated for rejection during the study period. Eight out of 43 grafts failed irreversibly as a result of other causes than graft rejection, two grafts failed as a consequence of intractable glaucoma, and six because of presumed slow endothelial decompensation.
In the group of cases, 12 out of 21 (57%) could be considered as high risk and in the group of controls 19 out of 43 (44%).
Patient, donor, and graft characteristics of cases and controls are presented in Table 1 . No significant diVerences were found between the two groups with respect to these characteristics. The indications for PKP are shown in Table 2 .
DIAGNOSIS OF REJECTION
The time between PKP and the first rejection episode, not necessarily ending in graft failure, was used to analyse graft outcome. The diagnosis of immune mediated allograft rejection was based on generally accepted criteria. 37 All corneal grafts had to become clear after surgery and a diagnosis of rejection was not made for at least 10 days after surgery. Rejection episodes were not diagnosed during a period of elevated ocular pressure. The presence of a "Khodadoust line" was considered a pathognomonic sign of graft rejection. In the absence of a Khodadoust rejection line, graft rejection was diagnosed by the presence of cells in the anterior chamber, in combination with an increase in (partial) corneal thickness and/or keratic precipitates limited to the graft. For patients with a history of HSK, graft rejection, and recurrence of herpes simplex virus (HSV) infection needed to be diVerentiated. If no Khodadoust line was observed, additional tests were needed to diagnose HSV infection. Aqueous humour was obtained by paracentesis of the anterior chamber to determine intraocular antibody production against HSV, expressed as the Goldmann-Witmer coeYcient for HSV. Also, PCR analysis of HSV DNA was performed 38 to exclude an active ocular herpes simplex infection. Herpes infected cases were excluded from analysis in this study.
METHODS
Donor procurement and medical procedures did not change during the study period. All donor corneas were obtained from Bio Implant Service and the Dutch Eye Bank, Amsterdam, Netherlands. The donor corneas were organ culture preserved as described by Pels et al. 39 All donor corneas were stored in organ culture of Eagle's minimum essential medium for at least 7 days with a maximum of 27 days. PKP procedures were performed by one of three ophthalmic surgeons using similar surgical techniques. All patients were treated with a combination of prednisolone eye ointment (0.5%, at bedtime) and local dexamethasone/ gentamicin eye drops (0.1%, six times daily) after surgery, for 4 weeks. At least 1-1.5 years after PKP, dexamethasone eye drops were applied and gradually tapered oV. If PKP was combined with a cataract extraction or removal of an intraocular lens, additional eye drops were given, containing a non-steroid antiinflammatory drug (0.1%, four times daily) during the first 3 months after surgery. Rejection reactions were treated with hourly applications of prednisolone acetate 1% eye drops and three periocular injections with 0.1% dexamethasone, given every other day. Graft rejection has led to irreversible graft failure in nine out of 21 cases. Corneal tissue was used for retrospective DNA HLA typing. For this purpose, corneal tissue of the recipients and corneal rims of donor corneas were collected at the time of surgery and stored frozen (at −80°C). After repeated transplantation blood samples containing peripheral blood mononuclear cells were taken from recipients to obtain DNA. Corneal tissues and blood derived cell suspensions were subjected to DNA extraction using the Qiagen DNA extraction kit (Boehringer, Mannheim, Germany) for blood and tissues, according to the manufacturer's instructions. DNA solutions were stored at −80°C until further amplification. The diagnosis of rejection at the end of the follow up was made before the HLA typing was known. HLA typing was done without knowledge of graft outcome. This molecular typing of HLA-A, HLA-B, and HLA-DRB1 (all low resolution) was performed according to a reverse hybridisation line probe assay as described by the manufacturer of InnoLiPa (Innogenetics, Gent, Belgium). 40 Typing data were available in all 64 donor/ recipient pairs for HLA-DR. For HLA-A and HLA-B one and five pairs were not available respectively, owing to shortness of donor DNA (n = 2), technical problems with PCR (n = 1), and problems with analysing the Lipa test results for HLA-B (n = 3). Analysis was performed both on the broad HLA typing level (A1, A2, A3, A9, A10, A11, A19, A28, B5, B7, B8, B12, B13, B14, B15, B16, B17, B18, B21, B22, B27, B35, B37, B40, B41, B42, B53, B70, DR1, DR2, DR3, DR4, DR5, DR6, DR7, DR8, DR9, DR10) and split typing level (splits from A9, A10, A19, A28, B5, B12, B16, B17, B21, B22, B70, DR2, DR3, DR5, DR6).
ANALYSIS AND STATISTICS
Comparability of patient, donor, and graft covariates between cases and controls were analysed using the 2 test for categorical variables and the independent T test for continuous covariates. To analyse rejection free graft survival, cases and controls were subdivided into a group with and a group without matched HLA subtypes. The group with matches consisted of cases and controls with one or two matches of HLA-A, HLA-B, or HLA-DR. Unadjusted survival probabilities for the total group as well as the high and low risk group were estimated using Kaplan-Meier statistics and diVerences were assessed using the log rank test. 41 All tests were two sided and a p value of less than 0.05 was taken as statistically significant.
To assess the clinical relevance of matching we used Cox regression analysis estimating the odds ratios (OR) and 95% confidence intervals for the association between HLA matching per HLA locus and duration of rejection free graft survival, adjusting for confounding variables. Covariates were chosen for inclusion in the model if they were mildly correlated (p<0.20) with rejection according to univariate analysis. Using this selection criterion, only vascularisation of the recipient cornea was included in the model (p = 0.12).
Results
The median follow up period of the control group (n = 43) was 2.6 years (range 1-4 years). The median time until rejection of the case group (n = 21) was 9 months (range 12 days to 1 year and 11 months).
The maximum number of matches based on split typing for a patient in this study was three, which was detected in six controls and one case. The distribution of HLA-A, HLA-B, and HLA-DR split matches in cases and controls is shown in Table 3 . Recalculation of split HLA DNA typing results into broad typing results did not yield significant diVerences between cases and controls with regard to HLA-A and HLA-B matching. However, an increased amount of broad HLA-DR matches was found compared to the amount of split HLA-DR matches in four cases.
Corneal graft recipient-donor pairs with HLA-A matches had a longer rejection free graft survival compared with corneal grafts without HLA-A matches (log rank test, p = 0.034, Fig 1) . We observed a trend towards a prolonged rejection free graft survival with increasing numbers of HLA-A matches. No diVerence was observed in rejection free graft survival time between cases and controls with respect to HLA-B matches (Fig 2) and HLA-DR matches (Fig 3) .
Analysing rejection free graft survival for the high risk (n = 31) and low risk (n = 33) group separately, a stronger association between longer rejection free graft survival and HLA-A matching in the low risk group was found (log rank test, p = 0.013). Graft survival was not significantly longer with respect to HLA-B matches in the high or low risk group (data not shown). Analysis of the HLA-A and HLA-B matches together showed no eVect in the total group or in the high risk group. However, we observed a beneficial eVect of matching for HLA-DR in the high risk group (log rank test, p = 0.030, Fig 4) . According to Cox regression analysis, after adjustment for vascularisation of the recipient cornea, HLA-A matched transplants (one or two HLA-A matches) were almost three times less likely to reject than HLA-A unmatched transplants (Table 4) . HLA-DR matched transplants were slightly, but not significantly, less likely to reject (Table 4) .
Discussion
The results showed that the presence of HLA-A matches was associated with prolonged rejection free graft survival. When considering patients at high risk for rejection, a beneficial eVect of HLA-DR matches was shown. These HLA matches were found retrospectively in corneal graft recipients who received random donor corneas at the time of PKP.
Cases with and controls without an immune mediated graft rejection were analysed together according to their rejection free graft survival time. The first rejection episode, not necessarily leading to graft failure, was used as the end point of analysis. From an immunological point of view it is more appropriate to use rejection free graft survival time rather than time to immunological graft failure. Whether a rejection episode will lead to graft failure is dependent on treatment protocols of a rejection reaction used in diVerent transplantation centres. Furthermore, each rejection episode accelerates the postoperative loss of endothelial cells, resulting in earlier graft failure. 42 43 A major advantage of HLA DNA typing, as used in this study, is that this method is less prone to errors than serological typing techniques. 31 32 Discrepancy rates of 10-25% have been reported for serological HLA-DR typing in kidney transplantation. 29 DNA can be derived from any organic tissue, including corneal tissue, which is easily obtained at PKP 44 and nearly always available in contrast with blood samples necessary for serological typing.
The diagnosis of an immune mediated graft rejection is not always clearcut. Rejection and recurrence of HSK can be impossible to distinguish clinically and may coexist. 45 We excluded patients for whom it was not possible to diVerentiate between graft rejection and HSK.
Patient compliance is of great influence on graft survival. 6 In our study topical steroids were given for at least 1 year in all patients. All patients with graft rejection within 1 year were still using topical steroids. These data, however, are based on patient records and a contribution of patient compliance to graft rejection could not be fully excluded.
HLA-A and HLA-B antigens have been identified on corneal epithelium, stromal cells, and corneal endothelial cells. 19 46 47 The HLA class I antigens are targets for CD8+ cytotoxic T cells in the process of graft rejection. 21 Theoretically, matching for HLA-A and HLA-B therefore would reduce the amount of target antigens, which could lead to a decreased incidence of rejection. An accumulating number of authors suggested that HLA-A and HLA-B matching was associated with improved outcome of corneal graft survival in high risk recipients. 5 9-12 15 33 48 49 These data on HLA-A matching are in line with the results from our study. However, other studies, including the large Collaborative Corneal Transplantation Study, failed to demonstrate a correlation of HLA matches and graft survival. 16-18 50 A beneficial HLA-A matching eVect was observed in all risk categories with a stronger association in low risk cases by Boisjoly et al, 11 which is in accordance with our findings. In this study, HLA-B matches showed no significant eVects on graft rejection. This might be due to the overall low number of matches observed in this study at the polymorphic HLA-B locus. In previous studies, matching of HLA-B showed a beneficial eVect on corneal graft survival 5 10 12 and an adverse eVect in others. 18 20 Despite the fact that HLA-DR is considered to be important in renal transplantation, 29 the role of HLA-DR matching in corneal transplantation remains controversial. 49 51 Significant beneficial eVects of HLA-DR matching in high risk recipients were reported using RFLP typing techniques, 26 but a historical control group was used. Japanese studies 33 34 44 using DNA typing techniques reported a strong beneficial eVect of HLA-DP matching and no eVect of matching for HLA-DR. This may be explained by the overall low number of HLA-DR matches reported by this group, using donors and recipients from diVerent ethnic backgrounds. In our study, both donors and recipients originated mostly from the white population, and therefore from the same gene pool. This may add to the explanation of the high number of coincidental HLA-A and HLA-DR matches we observed. In some studies, a beneficial influence of HLA-DR matching could not be found in low or high risk recipients, 16 17 52 whereas in other studies an adverse eVect was reported. 28 51 However, in these studies serological typing techniques were used, which in general yield accurate broad but not split typing results. In our study HLA DNA typing included analysis of HLA split antigens. A beneficial eVect of HLA-DR matching in high risk recipients was shown. After conversion of HLA-DR split to broad antigens (data not shown), a significant eVect of matching could no longer be found, which is in line with the previously mentioned studies.
Expression of HLA-DR antigens carried on Langerhans cells has been demonstrated within normal corneal epithelium and stromal layers. 19 47 Migration and accumulation of Langerhans cells in the central part of the cornea, which is normally devoid of Langerhans cells 19 24 can be established by vascularisation and inflammation. 53 As a consequence of an increased number of Langerhans cells in the centre of the donor cornea, a rejection reaction may be provoked. 54 The beneficial eVect of HLA-DR matching for high risk recipients as reported in our study might be explained by a higher number of Langerhans cells in the central area of the cornea after transplantation in this high risk group.
A drawback of this study is the overall low number of included patients. Owing to the random distribution of corneal grafts a relatively small number of patients with more than one match at HLA-A, HLA-B, or HLA-DR loci was included. As a consequence it was not possible to evaluate combinations of HLA-A and HLA-B matches or to evaluate the eVect of HLA-DR in the absence of any HLA-A or HLA-B match.
Although the case and control group are comparable with respect to the characteristics mentioned in Table 1 , the indications for transplantation were not completely comparable, with Fuchs' dystrophy (n = 2) and keratoconus (n = 11) being present only in the control group. One of the two excluded cases (no donor corneal tissue available) was transplanted for Fuchs' dystrophy; if this patient had been included, the only remaining diVerence would have been the indication of keratoconus. Analysis of rejection free graft survival without considering these 11 patients showed the same results for the high risk group (a longer rejection free graft survival for HLA-DR matched transplants). Furthermore, rejection free graft survival was longer for HLA-A matched transplants in the total group (n = 52), despite the loss of power (p = 0.047).
We included controls with at least 1 year of follow up. However, rejections are still observed after 1 year. Therefore, further studies with a longer follow up time will be needed to show a beneficial long term outcome with matching.
Organ culture preservation of donor corneas, as used for all donor corneas in this study, allows time to allocate corneas based on HLA matching. Prospective DNA HLA typing and transportation of donor corneas over long distances to the most suitable recipient could give logistical problems if short term preservation techniques, such as McCarey-Kaufman medium, are used. The cost-benefit ratio of providing matched corneal grafts should be investigated in more detail. Especially in more heterogeneous populations where less coincidental HLA matches are expected, allocation of matched donor corneas could be more diYcult but also more eVective in preventing corneal graft rejection.
In conclusion, molecular typing of HLA-A, HLA-B, and HLA-DRB1 is an accurate method and oVers the possibility to perform HLA typing at any time postoperatively, using corneal derived DNA. Although all corneal graft recipients received random donor corneas, retrospectively a significantly higher number of HLA-A matches was found, in favour of recipients with longer rejection free graft survival. Furthermore, a beneficial eVect of matching for HLA-DR was shown for high risk recipients. These results add to the evidence that prospective molecular HLA-A and HLA-DR typing has a beneficial eVect upon graft survival.
